SEC Filing Summary: Synta Pharmaceuticals Corp. (8-K)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Synta Pharmaceuticals Corp. on April 15, 2011, regarding events occurring on April 14, 2011. The filing discloses the entry into a material definitive agreement for a common stock offering.
Key Financial Metrics
- Offering Size: 7,191,731 shares of common stock.
- Offering Price: $4.89 per share (closing price on April 14, 2011).
- Expected Net Proceeds: Approximately $34.8 million after deducting estimated expenses.
- Director Participation: Directors agreed to purchase an aggregate of 1,581,493 shares.
- Revenue, Profit, and Cash Flow: The filing text does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics.
Material Changes
The primary material change is the execution of common stock purchase agreements to raise capital. The offering is expected to close on or about April 20, 2011, subject to customary closing conditions. This represents a significant increase in the company's equity capital base upon closing.
Outlook, Risks, and Management Commentary
The offering is being made pursuant to a prospectus supplement dated April 14, 2011, and an accompanying prospectus dated August 28, 2008, under an existing effective shelf registration statement (File No. 333-152833). The filing includes a legal opinion regarding the issuance and sale of the shares. No specific forward-looking guidance, risk factors, or unusual items beyond the standard offering disclosures are detailed in this specific 8-K text.
Investor Verification Checklist
- Verify the final closing date of the offering (expected April 20, 2011).
- Confirm the final net proceeds received after all transaction expenses.
- Review the full Prospectus Supplement (dated April 14, 2011) for detailed use of proceeds and risk factors.
- Check subsequent filings for the actual number of shares issued and any changes in the offering price.